Corrilynn O Hileman
Overview
Explore the profile of Corrilynn O Hileman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
630
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaur H, Alluri R, Wu K, Kalayjian R, Bush W, Palella F, et al.
Antioxidants (Basel)
. 2024 Sep;
13(9).
PMID: 39334701
Ferroptosis is implicated in viral neuropathogenesis and may underlie HIV-associated neurocognitive impairment (NCI). Emerging data also suggest differences in brain iron transport by sex. We hypothesized that circulating ferritins that...
2.
Hmiel L, Zhang S, Obare L, Santana M, Wanjalla C, Titanji B, et al.
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000373
Atherosclerotic vascular disease disproportionately affects persons living with HIV (PLWH) compared to those without. The reasons for the excess risk include dysregulated immune response and inflammation related to HIV infection...
3.
Gandhi M, Hill L, Grochowski J, Nelson A, Koss C, Mayorga-Munoz F, et al.
Open Forum Infect Dis
. 2024 Apr;
11(4):ofae125.
PMID: 38628952
Background: Injectable cabotegravir (CAB)/rilpivirine (RPV) is the only combination long-acting (LA) antiretroviral regimen approved for HIV. RPV may not be effective among individuals with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance,...
4.
Longenecker C, Jones K, Hileman C, Okeke N, Gripshover B, Aifah A, et al.
JAMA Netw Open
. 2024 Mar;
7(3):e2356445.
PMID: 38441897
Importance: Despite higher atherosclerotic cardiovascular disease (ASCVD) risk, people with HIV (PWH) experience unique barriers to ASCVD prevention, such as changing models of HIV primary care. Objective: To test whether...
5.
Hileman C, Malakooti S, Patil N, Singer N, McComsey G
Front Immunol
. 2024 Feb;
15:1337406.
PMID: 38390319
Introduction: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may trigger autoimmune disease (AD) through initial innate immune activation with subsequent aberrations in adaptive immune cells leading to AD. While there are...
6.
Laper S, Hileman C, Block G, Erlandson K, Krsak M
AIDS Res Hum Retroviruses
. 2023 Oct;
40(5):293-300.
PMID: 37823750
We sought to describe the prevalence of and motivation for cannabis use and whether legalization of cannabis impacts the frequency and perceived risks and benefits of use in people living...
7.
Davey C, Longenecker C, Brinza E, McCabe M, Hileman C, Vedanthan R, et al.
AIDS Care
. 2023 Feb;
35(12):1911-1918.
PMID: 36755400
The COVID-19 pandemic's impact on cardiovascular health behaviors including diet, physical activity, medication adherence, and self-care among people living with HIV (PLWH) remains unknown. Using qualitative analyses, we examined the...
8.
Hileman C, Durieux J, Janus S, Bowman E, Kettelhut A, Nguyen T, et al.
Clin Infect Dis
. 2022 Oct;
76(3):375-381.
PMID: 36208157
Background: Heroin use may work synergistically with human immunodeficiency virus (HIV) infection to cause greater immune dysregulation than either factor alone. Unraveling how this affects end-organ disease is key as...
9.
Hileman C, Bowman E, Gabriel J, Kettelhut A, Labbato D, Smith C, et al.
J Acquir Immune Defic Syndr
. 2022 Jan;
89(5):519-526.
PMID: 35001040
Background: Altered gut integrity is central to HIV-related immune activation. Opioids may promote similar changes in gut permeability and/or increase systemic inflammation, potentially augmenting processes already occurring in people with...
10.
Hagins D, Kumar P, Saag M, Wurapa A, Brar I, Berger D, et al.
J Acquir Immune Defic Syndr
. 2021 Aug;
88(1):86-95.
PMID: 34397746
Background: With the highest rates of HIV/AIDS in the United States, Black Americans are still underrepresented in HIV medical research. Setting: BRAAVE (NCT03631732) is a randomized, phase 3b, multicenter, open-label...